Pure Global AI
NCT06329882Not yet recruiting

Doxycycline in Type II Diabetes

Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
Mostafa BahaaPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
Sitagliptin 100mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mostafa Bahaa
Funder
Tanta University
Timeline & enrollment
Phase
Phase 1/2
Start date
Mar 30, 2024
End date
Apr 20, 2025
Enrollment
60 participants
Primary outcome

Change in glycemic profile,Change in glycemic profile

Summary

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by
 hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the
 progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of
 the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06329882
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06329882 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Mostafa Bahaa and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.